266 related articles for article (PubMed ID: 28425622)
1. Targeted Disruption of NF1 in Osteocytes Increases FGF23 and Osteoid With Osteomalacia-like Bone Phenotype.
Kamiya N; Yamaguchi R; Aruwajoye O; Kim AJ; Kuroyanagi G; Phipps M; Adapala NS; Feng JQ; Kim HK
J Bone Miner Res; 2017 Aug; 32(8):1716-1726. PubMed ID: 28425622
[TBL] [Abstract][Full Text] [Related]
2. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
[TBL] [Abstract][Full Text] [Related]
3. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
4. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
[TBL] [Abstract][Full Text] [Related]
5. Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype.
Bai X; Dinghong Q; Miao D; Goltzman D; Karaplis AC
Am J Physiol Endocrinol Metab; 2009 Jan; 296(1):E79-88. PubMed ID: 18984852
[TBL] [Abstract][Full Text] [Related]
6. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism.
Feng JQ; Ward LM; Liu S; Lu Y; Xie Y; Yuan B; Yu X; Rauch F; Davis SI; Zhang S; Rios H; Drezner MK; Quarles LD; Bonewald LF; White KE
Nat Genet; 2006 Nov; 38(11):1310-5. PubMed ID: 17033621
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic role of Fgf23 in Hyp mice.
Liu S; Zhou J; Tang W; Jiang X; Rowe DW; Quarles LD
Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E38-49. PubMed ID: 16449303
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromin inactivation impairs osteocyte development in Nf1Prx1 and Nf1Col1 mouse models.
Kühnisch J; Seto J; Lange C; Stumpp S; Kobus K; Grohmann J; Elefteriou F; Fratzl P; Mundlos S; Kolanczyk M
Bone; 2014 Sep; 66():155-62. PubMed ID: 24947449
[TBL] [Abstract][Full Text] [Related]
9. Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.
Kühnisch J; Seto J; Lange C; Schrof S; Stumpp S; Kobus K; Grohmann J; Kossler N; Varga P; Osswald M; Emmerich D; Tinschert S; Thielemann F; Duda G; Seifert W; El Khassawna T; Stevenson DA; Elefteriou F; Kornak U; Raum K; Fratzl P; Mundlos S; Kolanczyk M
PLoS One; 2014; 9(1):e86115. PubMed ID: 24465906
[TBL] [Abstract][Full Text] [Related]
10. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.
Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD
FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898
[TBL] [Abstract][Full Text] [Related]
11. Deletion of PTH rescues skeletal abnormalities and high osteopontin levels in Klotho-/- mice.
Yuan Q; Sato T; Densmore M; Saito H; Schüler C; Erben RG; Lanske B
PLoS Genet; 2012; 8(5):e1002726. PubMed ID: 22615584
[TBL] [Abstract][Full Text] [Related]
12. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
[TBL] [Abstract][Full Text] [Related]
13. FGF23 Neutralizing Antibody Partially Improves Bone Mineralization Defect of HMWFGF2 Isoforms in Transgenic Female Mice.
Xiao L; Homer-Bouthiette C; Hurley MM
J Bone Miner Res; 2018 Jul; 33(7):1347-1361. PubMed ID: 29502359
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD bone.
Pereira RC; Salusky IB; Bowen RE; Freymiller EG; Wesseling-Perry K
Bone; 2019 Oct; 127():626-634. PubMed ID: 31377240
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo.
Rhee Y; Bivi N; Farrow E; Lezcano V; Plotkin LI; White KE; Bellido T
Bone; 2011 Oct; 49(4):636-43. PubMed ID: 21726676
[TBL] [Abstract][Full Text] [Related]
16. Elevated FGF23 in a patient with hypophosphatemic osteomalacia associated with neurofibromatosis type 1.
Sahoo SK; Kushwaha P; Bharti N; Khedgikar V; Trivedi R; Agrawal V; Ahmad N; Zaidi G; Pal L; Ito N; Bhatia E
Bone; 2019 Dec; 129():115055. PubMed ID: 31476437
[TBL] [Abstract][Full Text] [Related]
17. Conditional Deletion of Murine Fgf23: Interruption of the Normal Skeletal Responses to Phosphate Challenge and Rescue of Genetic Hypophosphatemia.
Clinkenbeard EL; Cass TA; Ni P; Hum JM; Bellido T; Allen MR; White KE
J Bone Miner Res; 2016 Jun; 31(6):1247-57. PubMed ID: 26792657
[TBL] [Abstract][Full Text] [Related]
18. FGF23-regulated production of Fetuin-A (AHSG) in osteocytes.
Mattinzoli D; Rastaldi MP; Ikehata M; Armelloni S; Pignatari C; Giardino LA; Li M; Alfieri CM; Regalia A; Riccardi D; Messa P
Bone; 2016 Feb; 83():35-47. PubMed ID: 26476373
[TBL] [Abstract][Full Text] [Related]
19. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.
Wang W; Nyman JS; Ono K; Stevenson DA; Yang X; Elefteriou F
Hum Mol Genet; 2011 Oct; 20(20):3910-24. PubMed ID: 21757497
[TBL] [Abstract][Full Text] [Related]
20. Bone mineralization is regulated by signaling cross talk between molecular factors of local and systemic origin: the role of fibroblast growth factor 23.
Sapir-Koren R; Livshits G
Biofactors; 2014; 40(6):555-68. PubMed ID: 25352227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
